New data in metastatic uveal #melanoma at #ASCO26 suggest that darovasertib + crizotinib may offer a new treatment option for patients with limited alternatives. Dr Orloff reviews findings showing improved PFS and response rates versus standard therapy. ecancer.org/en/video/129...
Dr Marlana Orloff speaks to ecancer about the phase 2/3 OptimUM-02 trial.
This trial evaluates darovasertib (PKC inhibitor) combined with crizotinib (MET inh
